email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
841 - 855
of 3612 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
Suzhou Kintor Starts US Trial of ALK-1 mAb for Hepatocellular Carcinoma
$5.00
Available
What Biopharma Slowdown? OrbiMed Raising $1.1 Billion for Asia Companies; $4.75 Billion for Three Funds
$5.00
Available
Hansoh Signs $218 Million Agreement with NiKang for Oncology Asset
$5.00
Available
Inmagene Approved to Start US Trials of HutchMed Immune Disease Therapy
$5.00
Available
Junshi and Coherus Undaunted by US Rejection of Partnered PD-1
$5.00
Available
LianBio’s Partner BMS OK’d to Launch Cardiomyopathy Drug in US
$5.00
Available
Xbiome Acquires Global Rights to Microbiome Product for Ulcerative Colitis
$5.00
Available
Xbiome Acquires Global Rights to Microbiome Product for Ulcerative Colitis
$5.00
Available
Chimera Bio Wins $7.5 Million Asia Award for Novel CAR-T Technology
$5.00
Available
RVAC Completes B Round for mRNA Drugs, Bringing Total Raised to $140 Million
$5.00
Available
Huadong Medicine Acquires Rights to Four Ashvattha Candidates for $45 Million
$5.00
Available
I-Mab and VMS Partner to IPO a SPAC in HK for a China Life Science Company
$5.00
Available
Viva Invests $60 Million in China RNAi JV it Formed with Arrowhead
$5.00
Available
Sinorda and Porton Partner to Advance Cell and Gene Therapy Products
$5.00
Available
Shanghai STAR Exchange Biologic and Medicine Index Launches May 9
$5.00
Available